New Reata cancer drug reduces tumors
16th Nov 2006, 16:04 GMT
Reata Pharmaceuticals has presented preclinical data showing that its investigatonal drug candidate RTA 402 prevented the development of lung cancer in a mouse model of the disease.
Latest news from Pharmaceutical Business Review Latest News:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol